Table 2.

Aramchol Versus Placebo: Longitudinal Full Liver Fat Mapping Using Magnetic Resonance Imaging Proton Density Fat-Fraction (MRI PDFF)

	Aramchol (n=24)			Placebo (n=22)			Difference
Liver Segments	Baseline	Posttreatment	P-Value	Baseline	Posttreatment	P-Value	P-Value
1	15.4 (6.9)	14.3 (7.9)	0.2989	13.3 (5.8)	11.6 (5.0)	0.1890	0.7589
2	14.1 (6.3)	13.3 (7.3)	0.4123	11.9 (6.2)	10.2 (5.0)	0.1779	0.5409
3	14.8 (6.5)	13.7 (7.7)	0.3371	13.2 (6.6)	11.7 (6.1)	0.2744	0.8000
4a	15.7 (6.8)	14.3 (7.6)	0.1993	13.0 (6.1)	11.5 (5.0)	0.2361	0.9609
4b	15.8 (6.9)	14.3 (7.8)	0.2118	13.3 (6.4)	11.9 (5.5)	0.3042	0.9486
5	15.6 (7.1)	14.6 (8.3)	0.3967	13.0 (5.5)	11.9 (6.1)	0.4579	0.9407
6	15.5 (7.1)	14.3 (8.0)	0.2709	13.5 (6.5)	11.3 (6.3)	0.1236	0.6302
7	16.5 (7.8)	15.2 (8.5)	0.2360	14.3 (6.3)	13.1 (6.6)	0.4051	0.9281
8	16.6 (7.7)	15.6 (8.5)	0.3820	14.4 (6.2)	13.3 (6.9)	0.4348	0.9756
MRI PDFF average	15.6 (6.9)	14.4 (7.8)	0.2400	13.3 (5.9)	11.9 (5.6)	0.2648	0.9308
MRE average (kPa)	2.6 (0.6)	2.5 (0.5)	0.4777	2.4 (0.5)	2.5 (0.6)	0.7151	0.4459
VCTE (kPa)
Median	6.7 (2.3)	7.4 (3.3)	0.2582	6.3 (2.8)	5.2 (1.4)	0.0321	0.0307
IQR	1.0 (0.5)	1.3 (0.8)	0.1319	0.9 (0.6)	0.8 (0.5)	0.2175	0.0542
IQR/M	15.6 (8.4)	16.3 (6.2)	0.7102	14.4 (6.8)	13.6 (6.9)	0.7256	0.6068
Controlled attenuation parameter (dB/m)
Median	330.3 (41.2)	313.5 (59.4)	0.1912	316.4 (70.9)	312.5 (54.8)	0.8193	0.5287
IQR	32.8 (14.9)	35.0 (20.5)	0.6577	33.3 (18.8)	35.9 (16.9)	0.6823	0.9615

Data are expressed as means (sd) or mean difference with p-values in parentheses. Associated p-values are from t test. P-values in bold denote statistical significance < 0.05.

MRI-PDFF, Magnetic Resonance Imaging Proton Density Fat Fraction;

MRI PDFFs measured in all nine liver segments are used to calculate segmental and overall fat fraction averages at baseline and posttreatment between Drug and placebo group.

Only reliable VCTE values used